Nintedanib in chILD: a small step, yes… but at least a step forward in a marathon!
- PMID: 36731900
- DOI: 10.1183/13993003.01797-2022
Nintedanib in chILD: a small step, yes… but at least a step forward in a marathon!
Conflict of interest statement
Conflict of interest: D. Gozal has no conflicts of interest to disclose. M. Kolb reports being site PI for sponsored clinical trials for Roche and Boehringer Ingelheim, grants from Canadian Institute for Health Research, grants and personal fees for advisory board work from Boehringer Ingelheim and Roche Canada, chief editor allowance from the European Respiratory Society, personal fees for advisory board work from Horizon, Algernon, CSL Behring, DevPro, Bellerophon and BMS, personal fees for adjudication committee work from United Therapeutics, and personal fees for data monitoring committee work from LabCorp, outside the submitted work.
Comment on
-
Nintedanib in children and adolescents with fibrosing interstitial lung diseases.Eur Respir J. 2023 Feb 2;61(2):2201512. doi: 10.1183/13993003.01512-2022. Print 2023 Feb. Eur Respir J. 2023. PMID: 36041751 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical